# A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

> **NCT00492297** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 83 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)

## Key facts

- **NCT ID:** NCT00492297
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492297, "A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00492297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*